President Donald Trump is set to reveal on Thursday a new partnership with pharmaceutical company Regeneron designed to reduce medication costs as part of his administration’s most-favored-nation drug pricing program.
Under the terms of the agreement, Regeneron will reduce prices for both existing and upcoming medications within Medicaid and offer its cholesterol medication Praluent for $225 through the White House’s discount drug platform TrumpRx, according to details first reported by NOTUS and verified by White House press secretary Karoline Leavitt.
This announcement arrives as the Trump administration continues highlighting economic relief efforts before November’s midterm elections, with American families reporting financial strain from elevated healthcare, fuel, grocery, and other essential living costs.
The partnership represents one of several most-favored-nation agreements the Trump administration has negotiated with pharmaceutical companies to align U.S. drug costs with those in other developed countries. Following Trump’s public correspondence last July to leadership at 17 major pharmaceutical firms regarding this matter, Regeneron becomes the last of those companies to reach an agreement with his administration.
The deal also includes Regeneron’s pledge to invest approximately $10 billion in domestic pharmaceutical manufacturing, according to NOTUS reporting. Trump’s previous agreements have typically provided companies with tariff relief in exchange for such manufacturing commitments.
While Trump and his Department of Health and Human Services have promoted his drug-pricing agreements as groundbreaking, the specific terms of these contracts have remained confidential.
When congressional members requested contract details this week, Health Secretary Robert F. Kennedy Jr. indicated his department would release available information that doesn’t contain proprietary data or trade secrets. Both Trump and Kennedy have encouraged Congress to make these agreements legally binding.
Medication costs for American patients vary based on multiple elements, including market competition for treatments and insurance benefits. The majority of Americans receive coverage through employment, individual insurance markets, or government programs such as Medicaid and Medicare, which provide protection from most expenses.
While Medicaid patients, covered under the joint state and federal program for low-income individuals, currently pay minimal co-payments of just a few dollars for prescriptions, reduced drug prices could benefit state budgets that support these programs.
